JP2008538751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538751A5 JP2008538751A5 JP2008505990A JP2008505990A JP2008538751A5 JP 2008538751 A5 JP2008538751 A5 JP 2008538751A5 JP 2008505990 A JP2008505990 A JP 2008505990A JP 2008505990 A JP2008505990 A JP 2008505990A JP 2008538751 A5 JP2008538751 A5 JP 2008538751A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- surfactant
- particle size
- formulation
- average particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002105 nanoparticle Substances 0.000 claims 14
- 239000003381 stabilizer Substances 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 7
- 239000012458 free base Substances 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 5
- 229960000607 ziprasidone Drugs 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 239000002280 amphoteric surfactant Substances 0.000 claims 2
- 239000003945 anionic surfactant Substances 0.000 claims 2
- 239000003093 cationic surfactant Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960003474 ziprasidone hydrochloride Drugs 0.000 claims 1
- ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 claims 1
- 229960004487 ziprasidone mesylate Drugs 0.000 claims 1
- WLQZEFFFIUHSJB-UHFFFAOYSA-N ziprasidone mesylate trihydrate Chemical compound O.O.O.CS(O)(=O)=O.C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 WLQZEFFFIUHSJB-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67112405P | 2005-04-13 | 2005-04-13 | |
| PCT/IB2006/001094 WO2006109183A1 (en) | 2005-04-13 | 2006-04-10 | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538751A JP2008538751A (ja) | 2008-11-06 |
| JP2008538751A5 true JP2008538751A5 (enExample) | 2009-05-21 |
Family
ID=36602931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505990A Withdrawn JP2008538751A (ja) | 2005-04-13 | 2006-04-10 | ナノ粒子組成物を持続放出するための注射用デポ製剤および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080193542A1 (enExample) |
| EP (1) | EP1874268A1 (enExample) |
| JP (1) | JP2008538751A (enExample) |
| KR (1) | KR20070119678A (enExample) |
| CN (1) | CN101166514A (enExample) |
| AU (2) | AU2006233345A1 (enExample) |
| BR (1) | BRPI0609299A2 (enExample) |
| CA (1) | CA2605153A1 (enExample) |
| IL (1) | IL186131A0 (enExample) |
| MX (1) | MX2007012103A (enExample) |
| NZ (1) | NZ561950A (enExample) |
| RU (1) | RU2407529C2 (enExample) |
| WO (1) | WO2006109183A1 (enExample) |
| ZA (1) | ZA200708188B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| WO2001032148A1 (en) | 1999-10-29 | 2001-05-10 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
| BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
| US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| EP1901722A4 (en) * | 2005-06-20 | 2011-06-15 | Elan Pharma Int Ltd | NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS |
| MX2007016151A (es) * | 2005-06-20 | 2008-03-06 | Elan Pharma Int Ltd | Composiciones de liberacion controlada y en forma de nano-particulas que comprenden compuestos aril-heterociclicos. |
| AU2008274185B2 (en) * | 2007-07-12 | 2014-07-03 | Janssen Sciences Ireland Uc | Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
| EP2629775A4 (en) | 2010-10-18 | 2014-06-11 | Dainippon Sumitomo Pharma Co | INJECTABLE FORMULATION WITH DELAYED RELEASE |
| CA2832410C (en) | 2011-04-15 | 2019-07-23 | Janssen Pharmaceutica Nv | Freeze dried drug nanosuspensions |
| CN104814926A (zh) * | 2015-04-08 | 2015-08-05 | 中国药科大学 | 一种鲁拉西酮纳米混悬剂及其制备方法 |
| US20170079985A1 (en) * | 2015-09-21 | 2017-03-23 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| JP2020511483A (ja) | 2017-03-20 | 2020-04-16 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 徐放性オランザピン製剤 |
| CN109998991A (zh) * | 2019-04-28 | 2019-07-12 | 中国药科大学 | 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法 |
| KR102847306B1 (ko) * | 2021-08-13 | 2025-08-18 | 단국대학교 천안캠퍼스 산학협력단 | 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| MXPA05002561A (es) * | 2002-10-25 | 2005-05-05 | Pfizer Prod Inc | Nuevas formulaciones de liberacion prolongada inyectables. |
| AU2003300814A1 (en) * | 2002-12-04 | 2004-06-23 | Dr. Reddy's Laboratories Inc. | Polymorphic forms of ziprasidone and its hydrochloride |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
-
2006
- 2006-04-10 KR KR1020077023308A patent/KR20070119678A/ko not_active Abandoned
- 2006-04-10 NZ NZ561950A patent/NZ561950A/en not_active IP Right Cessation
- 2006-04-10 WO PCT/IB2006/001094 patent/WO2006109183A1/en not_active Ceased
- 2006-04-10 BR BRPI0609299-3A patent/BRPI0609299A2/pt not_active IP Right Cessation
- 2006-04-10 CN CNA2006800144209A patent/CN101166514A/zh active Pending
- 2006-04-10 EP EP06744618A patent/EP1874268A1/en not_active Withdrawn
- 2006-04-10 JP JP2008505990A patent/JP2008538751A/ja not_active Withdrawn
- 2006-04-10 RU RU2007137846/15A patent/RU2407529C2/ru not_active IP Right Cessation
- 2006-04-10 AU AU2006233345A patent/AU2006233345A1/en not_active Abandoned
- 2006-04-10 MX MX2007012103A patent/MX2007012103A/es not_active Application Discontinuation
- 2006-04-10 CA CA002605153A patent/CA2605153A1/en not_active Abandoned
- 2006-04-10 US US11/911,457 patent/US20080193542A1/en not_active Abandoned
-
2007
- 2007-09-20 IL IL186131A patent/IL186131A0/en unknown
- 2007-09-25 ZA ZA200708188A patent/ZA200708188B/xx unknown
-
2010
- 2010-05-05 AU AU2010201801A patent/AU2010201801A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538751A5 (enExample) | ||
| WO2007086914A3 (en) | Nanoparticulate clopidogrel formulations | |
| NO20080202L (no) | Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer | |
| ES2526092T3 (es) | Formulaciones de olanzapina en nanopartículas inyectables | |
| JP2013542981A5 (enExample) | ||
| NO20073334L (no) | Nanopartikulaert benzotiofenformuleringer | |
| WO2007100466A3 (en) | Nanoparticulate carvedilol formulations | |
| RU2007137846A (ru) | Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц | |
| NZ573555A (en) | Nanoparticulate posaconazole formulations | |
| BRPI0705488A (pt) | composição nanoparticulada estável, métodos de preparar a mesma e de prevenir e/ou tratar uma infecção bacteriana, composição farmacêutica, e, forma de dosagem | |
| ES2935158T3 (es) | Composición farmacéutica de nilotinib | |
| JP2013542945A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| JP2011518842A5 (enExample) | ||
| JP2009527505A5 (enExample) | ||
| NO20076628L (no) | Nanopartikkulaere sammensetninger med kontrollert frigjoring som omfatter arylheterosykliske forbindelser | |
| WO2008039406A3 (en) | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist | |
| JP2015520241A5 (enExample) | ||
| JP2004534739A5 (enExample) | ||
| WO2008030209A3 (en) | Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor | |
| JP2014534215A5 (enExample) | ||
| WO2012068476A3 (en) | Poly(vinyl benzoate) nanoparticles for molecular delivery | |
| WO2006088337A1 (en) | A base forming drug-layered silicate hybrid containing basic polymer and its synthesis method | |
| WO2007146943A3 (en) | Nanoparticulate kinase inhibitor formulations | |
| JP2009512691A5 (enExample) |